These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7360001)

  • 1. Spectrophotofluorometric evidence of negatively cooperative binding of warfarin and phenylbutazone to human serum albumin.
    Madsen BW; Tearne PD
    Life Sci; 1980 Jan; 26(3):173-9. PubMed ID: 7360001
    [No Abstract]   [Full Text] [Related]  

  • 2. Cooperative interaction of warfarin and phenylbutazone with human serum albumin.
    Madsen BW; Ellis GM
    Biochem Pharmacol; 1981 Jun; 30(11):1169-73. PubMed ID: 7271816
    [No Abstract]   [Full Text] [Related]  

  • 3. Warfarin metabolites: stereochemical aspects of protein binding and displacement by phenylbutazone.
    Chan E; McLachlan AJ; Rowland M
    Chirality; 1993; 5(8):610-5. PubMed ID: 8305289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of phenylbutazone, tolbutamide, and clofibric acid on binding of racemic warfarin and its enantiomers to human serum albumin.
    Veronich K; White G; Kapoor A
    J Pharm Sci; 1979 Dec; 68(12):1515-8. PubMed ID: 529041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Participation of the lone tryptophan residue of rat alpha-foetoprotein in its drug-binding sites. Comparison with rat serum albumin.
    Hervé F; Martin MT; Rajkowski K; Dessen P; Cittanova N
    Biochem J; 1987 May; 244(1):81-5. PubMed ID: 2444212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein-binding high-performance frontal analysis of (R)- and (S)-warfarin on HSA with and without phenylbutazone.
    He J; Shibukawa A; Tokunaga S; Nakagawa T
    J Pharm Sci; 1997 Jan; 86(1):120-5. PubMed ID: 9002471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for a large and flexible region of human serum albumin possessing high affinity binding sites for salicylate, warfarin, and other ligands.
    Kragh-Hansen U
    Mol Pharmacol; 1988 Aug; 34(2):160-71. PubMed ID: 3412320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the aflatoxin B1-binding site of rat albumin.
    Dirr HW; Schabort JC
    Biochim Biophys Acta; 1987 Jul; 913(3):300-7. PubMed ID: 3109487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retention data methods for the determination of drug-protein binding parameters by high-performance liquid chromatography.
    Sebille B; Thuaud N; Tillement JP
    J Chromatogr; 1981 Jan; 204():285-91. PubMed ID: 7217256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular basis of sulindac competition with specific markers for the major binding sites on human serum albumin.
    Russeva VN; Zhivkova ZD
    Arzneimittelforschung; 2003; 53(3):174-81. PubMed ID: 12705172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An in vitro study of drug displacement interactions: warfarin-salicylate and warfarin-phenylbutazone.
    Aarons LJ; Schary WL; Rowland M
    J Pharm Pharmacol; 1979 May; 31(5):322-30. PubMed ID: 37303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Albumin-binding interactions of sodium valproate.
    Fleitman JS; Bruni J; Perrin JH; Wilder BJ
    J Clin Pharmacol; 1980; 20(8-9):514-7. PubMed ID: 6776162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of competitive displacement agents to resolve albumin binding problems observed during the development of a radioimmunoassay for ICI 215001.
    Ballard P; Malone MD; Law B
    J Pharm Biomed Anal; 1994 Jan; 12(1):47-52. PubMed ID: 7909237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding of certain acidic drugs to human albumin: theoretical and practical estimation of fundamental parameters.
    Tillement JP; Zini R; d' Athis P; Vassent G
    Eur J Clin Pharmacol; 1974 Jul; 7(4):307-13. PubMed ID: 4850753
    [No Abstract]   [Full Text] [Related]  

  • 15. A rapid method for the estimation of drug-albumin affinity constants in human plasma.
    Solomon HM; Thomas GB
    Clin Pharmacol Ther; 1971; 12(3):445-8. PubMed ID: 5567799
    [No Abstract]   [Full Text] [Related]  

  • 16. Vacancy affinity capillary electrophoresis to study competitive protein-drug binding.
    Erim FB; Kraak JC
    J Chromatogr B Biomed Sci Appl; 1998 Jun; 710(1-2):205-10. PubMed ID: 9686888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of drug binding interactions on human, rat and rabbit serum albumin using high-performance displacement chromatography.
    Aubry AF; Markoglou N; McGann A
    Comp Biochem Physiol C Pharmacol Toxicol Endocrinol; 1995 Nov; 112(3):257-66. PubMed ID: 8838677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of coumarins to site I of human serum albumin. Effect of the fatty acids.
    Zatón AM; Ferrer JM; Ruiz de Gordoa JC; Marquínez MA
    Chem Biol Interact; 1995 Jul; 97(2):169-74. PubMed ID: 7606814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-binding properties of human alpha-foetoprotein.
    Hirano K; Watanabe Y; Adachi T; Ito Y; Sugiura M
    Biochem J; 1985 Oct; 231(1):189-91. PubMed ID: 2415113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of valproic acid, its unsaturated metabolites and some structurally related fatty acids on the binding of warfarin and dansylsarcosine to human albumin.
    Panjehshahin MR; Bowmer CJ; Yates MS
    Biochem Pharmacol; 1991 Apr; 41(8):1227-33. PubMed ID: 1706921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.